,reactionmeddraversionpt,reactionmeddrapt,safetyreportid,reactionoutcome
0,22.1,Dyspnoea,17099892,
0,22.1,Skin exfoliation,17100533,
1,22.1,Mastication disorder,17100533,
2,22.1,Peripheral swelling,17100533,
3,22.1,Ear infection,17100533,
4,22.1,Skin discolouration,17100533,
5,22.1,Therapy cessation,17100533,
0,22.1,Gastric disorder,17102209,
1,22.1,Diarrhoea,17102209,
2,22.1,Fatigue,17102209,
3,22.1,Depressed mood,17102209,
4,22.1,Nausea,17102209,
0,22.1,Acute respiratory failure,17102382,
0,22.1,Disease progression,17102454,
1,22.1,Therapy cessation,17102454,
0,22.1,Myocardial infarction,17102718,
0,22.1,Therapy cessation,17102855,
1,22.1,Disease progression,17102855,
0,22.1,Death,17102922,
0,22.1,Palpitations,17103147,
0,22.1,Infusion related reaction,17103216,
1,22.1,Swollen tongue,17103216,
2,22.1,Rash,17103216,
3,22.1,Dyspnoea,17103216,
0,22.1,Paraesthesia,17103235,
0,22.1,Death,17103259,
0,22.1,Condition aggravated,17103463,
1,22.1,Fatigue,17103463,
2,22.1,Alopecia,17103463,
0,22.1,Antibiotic therapy,17103958,
0,22.1,Somnolence,17104395,
1,22.1,Nausea,17104395,
2,22.1,Vomiting,17104395,
3,22.1,Diarrhoea,17104395,
0,22.1,Diarrhoea,17104645,
1,22.1,Dehydration,17104645,
2,22.1,Vomiting,17104645,
0,22.1,Abdominal pain upper,17104663,
0,22.1,Confusional state,17104702,
0,22.1,Haemoglobin decreased,17104782,
0,22.1,Muscle spasms,17104912,
1,22.1,Middle insomnia,17104912,
0,22.1,Somnolence,17104922,
1,22.1,Dysphonia,17104922,
0,22.1,Fatigue,17105013,
1,22.1,Nausea,17105013,
0,22.1,Fatigue,17105077,
0,22.1,White blood cell count decreased,17107055,
0,22.1,Death,17109304,
0,22.1,Jaundice,17109488,
0,22.1,Myalgia,17109540,
1,22.1,Asthenia,17109540,
0,22.1,Off label use,17109627,
0,22.1,Neutropenia,17109733,
1,22.1,Fatigue,17109733,
0,22.1,Prostatic specific antigen increased,17109870,
1,22.1,Glomerular filtration rate decreased,17109870,
0,22.1,Drug ineffective,17110239,
0,22.1,Pain in jaw,17110389,
1,22.1,Pain in extremity,17110389,
2,22.1,Burning sensation,17110389,
3,22.1,Neck pain,17110389,
4,22.1,Chest pain,17110389,
0,22.1,Rash,17110580,
0,22.1,Therapy non-responder,17111077,
1,22.1,Therapy cessation,17111077,
0,22.1,Stomatitis,17111085,
0,22.1,Fatigue,17111097,
0,22.1,Memory impairment,17111129,
1,22.1,Product dose omission,17111129,
2,22.1,Fatigue,17111129,
0,22.1,Abdominal discomfort,17111217,
1,22.1,Flatulence,17111217,
0,22.1,Feeling abnormal,17111219,
1,22.1,Nocturia,17111219,
0,22.1,Pain in extremity,17111221,
1,22.1,Neuropathy peripheral,17111221,
2,22.1,Erythema,17111221,
0,22.1,Arthralgia,17111228,
1,22.1,Hot flush,17111228,
2,22.1,Bone pain,17111228,
3,22.1,Therapy cessation,17111228,
4,22.1,Pain,17111228,
5,22.1,Haematochezia,17111228,
6,22.1,Fatigue,17111228,
0,22.1,Decreased appetite,17111295,
1,22.1,Dizziness,17111295,
2,22.1,Dehydration,17111295,
3,22.1,Asthenia,17111295,
4,22.1,Diarrhoea,17111295,
0,22.1,Neutropenia,17111473,
1,22.1,Intentional product use issue,17111473,
0,22.1,Cerebrovascular accident,17111501,
0,22.1,Treatment noncompliance,17111596,
1,22.1,Product availability issue,17111596,
2,22.1,Therapy cessation,17111596,
0,22.1,Emergency care,17111698,
0,22.1,Back pain,17111870,
1,22.1,Stomatitis,17111870,
2,22.1,Alopecia,17111870,
0,22.1,Purulent discharge,17111884,
1,22.1,Groin abscess,17111884,
2,22.1,Tenderness,17111884,
3,22.1,Lymphadenopathy,17111884,
4,22.1,Lymph node pain,17111884,
5,22.1,Condition aggravated,17111884,
6,22.1,Pain,17111884,
0,22.1,Diarrhoea,17111906,
1,22.1,Pyrexia,17111906,
2,22.1,Pain,17111906,
3,22.1,Vomiting,17111906,
4,22.1,Fatigue,17111906,
5,22.1,Palmar-plantar erythrodysaesthesia syndrome,17111906,
6,22.1,Nausea,17111906,
0,22.1,Impaired healing,17112105,
0,22.1,Rash,17112283,
1,22.1,Diarrhoea,17112283,
0,22.1,Bone cancer,17112425,
1,22.1,Urinary incontinence,17112425,
2,22.1,Therapy cessation,17112425,
0,22.1,Urinary tract infection,17113003,
0,22.1,Myocardial infarction,17113049,
0,22.1,Fatigue,17114191,
1,22.1,Decreased appetite,17114191,
0,22.1,Hospitalisation,17114340,
0,22.1,Hospitalisation,17114403,
0,22.1,Dyspnoea,17114453,
1,22.1,Chest discomfort,17114453,
2,22.1,Bronchospasm,17114453,
3,22.1,Feeling cold,17114453,
0,22.1,Diarrhoea,17114809,
0,22.1,Death,17115502,
0,22.1,Full blood count abnormal,17115821,
0,22.1,Urinary tract infection,17115857,
0,22.1,Flatulence,17116047,
1,22.1,Fatigue,17116047,
2,22.1,Muscle spasms,17116047,
0,22.1,Oral herpes,17116334,
0,22.1,Hot flush,17116838,
0,22.1,Dehydration,17117010,
0,22.1,Skin ulcer,17119721,
0,22.1,Renal injury,17119810,
0,22.1,Pulmonary embolism,17119889,
1,22.1,Sepsis,17119889,
2,22.1,Loss of consciousness,17119889,
3,22.1,Renal impairment,17119889,
0,22.1,Nausea,17119891,
1,22.1,Pain,17119891,
0,22.1,Death,17120126,
0,22.1,Amnesia,17120339,
0,22.1,Off label use,17120674,
0,22.1,Hypertension,17120677,
0,22.1,Malignant neoplasm progression,17120762,
0,22.1,Breast tenderness,17120904,
0,22.1,Asthenia,17121792,
0,22.1,Diarrhoea,17122036,
0,22.1,Burning sensation,17122039,
1,22.1,Poor quality sleep,17122039,
2,22.1,Hyperkeratosis,17122039,
3,22.1,Skin fissures,17122039,
4,22.1,Therapy change,17122039,
5,22.1,Hypoaesthesia,17122039,
0,22.1,Diarrhoea,17122043,
0,22.1,Abdominal pain,17122090,
0,22.1,Heart rate increased,17122150,
0,22.1,Breast tenderness,17122254,
0,22.1,Fatigue,17122304,
0,22.1,Cancer surgery,17122339,
0,22.1,Fatigue,17122402,
1,22.1,Deafness,17122402,
0,22.1,Thrombosis,17122408,
0,22.1,Disease progression,17122509,
0,22.1,Neoplasm malignant,17122529,
0,22.1,Cough,17122730,
1,22.1,Catheter site related reaction,17122730,
2,22.1,Skin exfoliation,17122730,
0,22.1,Atrial fibrillation,17127169,
0,22.1,Neuropathy peripheral,17127303,
1,22.1,Epistaxis,17127303,
0,22.1,Metastases to lung,17127415,
1,22.1,Lung disorder,17127415,
0,22.1,Fatigue,17127443,
1,22.1,Hypoacusis,17127443,
0,22.1,Death,17127752,
0,22.1,Adverse reaction,17128006,
1,22.1,Disease progression,17128006,
0,22.1,Cholecystitis acute,17034326,1
0,22.1,Chills,17034333,2
1,22.1,Hyperpyrexia,17034333,2
2,22.1,Vomiting,17034333,2
0,22.1,Cellulitis staphylococcal,17034362,6
0,22.1,Lower respiratory tract infection,17034389,1
1,22.1,Chest discomfort,17034389,1
2,22.1,Respiratory tract congestion,17034389,3
3,22.1,Urinary tract infection,17034389,3
4,22.1,Blood creatinine increased,17034389,1
5,22.1,Malignant neoplasm progression,17034389,6
6,22.1,Colitis,17034389,6
7,22.1,Blood urine present,17034389,6
0,22.1,Gastrointestinal carcinoma,17034417,6
0,22.1,Hypertension,17034440,6
1,22.1,Platelet count decreased,17034440,6
2,22.1,Palmar-plantar erythrodysaesthesia syndrome,17034440,6
3,22.1,Decreased appetite,17034440,6
4,22.1,Stomatitis,17034440,6
5,22.1,Nausea,17034440,6
6,22.1,Proteinuria,17034440,6
7,22.1,Dehydration,17034440,6
0,22.1,Metastases to bone,17034504,6
1,22.1,Death,17034504,5
2,22.1,Malignant neoplasm progression,17034504,6
0,22.1,Death,17034520,5
0,22.1,Post procedural complication,17034538,6
1,22.1,Prostatectomy,17034538,6
2,22.1,Endocarditis,17034538,6
3,22.1,Bacteraemia,17034538,6
0,22.1,Abdominal pain,17034577,3
1,22.1,Colon cancer metastatic,17034577,5
2,22.1,Constipation,17034577,1
3,22.1,Fatigue,17034577,3
4,22.1,Cardiac arrest,17034577,5
0,22.1,Retroperitoneal haemorrhage,17034623,3
0,22.1,Upper gastrointestinal haemorrhage,17034631,2
0,22.1,Angina pectoris,17034642,1
0,22.1,Osteonecrosis of jaw,17034651,1
0,22.1,Platelet count decreased,17034652,1
1,22.1,Dyspnoea,17034652,1
2,22.1,Thrombocytopenia,17034652,1
3,22.1,Alanine aminotransferase increased,17034652,1
4,22.1,Drug-induced liver injury,17034652,1
5,22.1,Aspartate aminotransferase increased,17034652,1
6,22.1,Nausea,17034652,1
7,22.1,Anaphylactic reaction,17034652,1
8,22.1,Asthma,17034652,1
0,22.1,Microangiopathic haemolytic anaemia,17034680,4
0,22.1,Hyperglycaemia,17034684,2
0,22.1,Neutropenia,17034705,6
1,22.1,Epistaxis,17034705,6
2,22.1,Aspartate aminotransferase increased,17034705,6
3,22.1,Anaemia,17034705,6
4,22.1,Alanine aminotransferase increased,17034705,6
5,22.1,Hypertension,17034705,6
6,22.1,Vomiting,17034705,6
7,22.1,Decreased appetite,17034705,6
8,22.1,Diarrhoea,17034705,6
9,22.1,Blood alkaline phosphatase increased,17034705,6
10,22.1,Nausea,17034705,6
11,22.1,Proteinuria,17034705,6
12,22.1,Rash,17034705,6
13,22.1,Leukopenia,17034705,6
14,22.1,Blood bilirubin increased,17034705,6
15,22.1,Pyrexia,17034705,6
16,22.1,Stomatitis,17034705,6
17,22.1,Fatigue,17034705,6
0,22.1,Prostatic specific antigen increased,17034733,6
1,22.1,Blood glucose increased,17034733,6
2,22.1,Pelvic pain,17034733,6
3,22.1,Arthralgia,17034733,6
4,22.1,Intervertebral disc disorder,17034733,6
0,22.1,Gait disturbance,17034810,6
1,22.1,Spinal pain,17034810,6
0,22.1,Cough,17034885,4
1,22.1,Hypersensitivity,17034885,4
2,22.1,Urticaria,17034885,4
3,22.1,Asthenia,17034885,4
4,22.1,Hypersensitivity,17034885,6
5,22.1,Nausea,17034885,6
0,22.1,Dermatitis bullous,17034886,2
0,22.1,Metastases to peritoneum,17034892,6
1,22.1,Ascites,17034892,6
2,22.1,Gait disturbance,17034892,2
3,22.1,Renal failure,17034892,6
4,22.1,Hypertension,17034892,6
5,22.1,Malignant neoplasm progression,17034892,6
6,22.1,Breast cancer metastatic,17034892,6
0,22.1,Disease progression,17034903,6
1,22.1,Recurrent cancer,17034903,6
2,22.1,Intentional product misuse,17034903,6
3,22.1,Drug ineffective,17034903,6
0,22.1,Disease progression,17034905,6
1,22.1,Drug ineffective,17034905,6
2,22.1,Recurrent cancer,17034905,6
0,22.1,Disease progression,17034914,6
1,22.1,Diarrhoea,17034914,6
2,22.1,Drug ineffective,17034914,6
3,22.1,Recurrent cancer,17034914,6
4,22.1,Nausea,17034914,6
0,22.1,Drug ineffective,17034915,6
1,22.1,Disease progression,17034915,6
2,22.1,Recurrent cancer,17034915,6
3,22.1,Intentional product misuse,17034915,6
0,22.1,Platelet count decreased,17034918,1
1,22.1,Asthenia,17034918,3
2,22.1,White blood cell count abnormal,17034918,1
3,22.1,Iron deficiency,17034918,6
4,22.1,Retching,17034918,3
5,22.1,Glaucoma,17034918,3
6,22.1,Psychomotor hyperactivity,17034918,3
7,22.1,Fatigue,17034918,3
8,22.1,Nausea,17034918,3
9,22.1,Blood magnesium decreased,17034918,3
10,22.1,Red blood cell count decreased,17034918,3
11,22.1,Blood potassium decreased,17034918,3
12,22.1,Constipation,17034918,1
13,22.1,Carbohydrate antigen 125 increased,17034918,6
14,22.1,Weight decreased,17034918,3
0,22.1,Disease progression,17034924,6
1,22.1,Drug ineffective,17034924,6
2,22.1,Recurrent cancer,17034924,6
3,22.1,Intentional product misuse,17034924,6
0,22.1,Nausea,17034925,6
1,22.1,Drug ineffective,17034925,6
2,22.1,Fatigue,17034925,6
3,22.1,Recurrent cancer,17034925,6
4,22.1,Disease progression,17034925,6
0,22.1,Nausea,17034927,3
1,22.1,Vomiting,17034927,1
2,22.1,Diarrhoea,17034927,6
3,22.1,Constipation,17034927,6
4,22.1,Fatigue,17034927,3
5,22.1,Death,17034927,5
6,22.1,Dizziness,17034927,6
7,22.1,Malaise,17034927,6
0,22.1,Back pain,17034952,1
1,22.1,Erythema,17034952,1
2,22.1,Feeling hot,17034952,1
0,22.1,Cardiac failure,17034977,1
1,22.1,Bronchitis,17034977,1
2,22.1,Cerebellar syndrome,17034977,1
0,22.1,Toxic encephalopathy,17035038,1
0,22.1,Neck pain,17035196,1
1,22.1,Arthralgia,17035196,1
0,22.1,Diarrhoea,17035254,6
1,22.1,Lichenoid keratosis,17035254,6
2,22.1,Off label use,17035254,6
3,22.1,Fatigue,17035254,6
0,22.1,Transaminases increased,17035293,1
1,22.1,Condition aggravated,17035293,3
2,22.1,Gamma-glutamyltransferase increased,17035293,3
0,22.1,Lymphocytic hypophysitis,17035333,2
0,22.1,Pneumonia fungal,17035352,6
1,22.1,Bone pain,17035352,6
2,22.1,Prostatic specific antigen increased,17035352,6
3,22.1,Neuropathy peripheral,17035352,3
4,22.1,Metastasis,17035352,6
5,22.1,Jaw disorder,17035352,6
6,22.1,Gait disturbance,17035352,6
7,22.1,Metastases to bone,17035352,6
8,22.1,Decreased appetite,17035352,6
9,22.1,Back pain,17035352,6
10,22.1,Malignant neoplasm progression,17035352,6
11,22.1,Muscular weakness,17035352,6
12,22.1,Mouth injury,17035352,6
13,22.1,Hypoaesthesia,17035352,6
14,22.1,Pain in jaw,17035352,6
15,22.1,Swelling face,17035352,6
16,22.1,Fungal infection,17035352,6
17,22.1,Fatigue,17035352,6
0,22.1,Dizziness,17035371,3
1,22.1,Headache,17035371,3
2,22.1,Diarrhoea,17035371,6
3,22.1,Weight decreased,17035371,6
0,22.1,Hydrothorax,17035457,3
1,22.1,Splenic lesion,17035457,6
2,22.1,Peripheral artery thrombosis,17035457,6
3,22.1,Pelvic venous thrombosis,17035457,6
4,22.1,Asthenia,17035457,6
5,22.1,Pulmonary embolism,17035457,3
6,22.1,Renal disorder,17035457,6
7,22.1,Pulmonary infarction,17035457,3
8,22.1,Pneumonia,17035457,3
9,22.1,Mediastinal disorder,17035457,3
10,22.1,Malignant neoplasm progression,17035457,6
0,22.1,Peripheral paralysis,17035467,2
1,22.1,Palmar-plantar erythrodysaesthesia syndrome,17035467,2
2,22.1,Haemochromatosis,17035467,2
0,22.1,Myocardial infarction,17035469,6
0,22.1,Tubulointerstitial nephritis,17035491,6
1,22.1,Breast mass,17035491,6
2,22.1,Pyrexia,17035491,6
3,22.1,Ascariasis,17035491,6
4,22.1,Rash,17035491,6
5,22.1,Thrombocytopenia,17035491,6
6,22.1,Metastases to bone,17035491,6
7,22.1,Anaemia,17035491,6
8,22.1,Proteinuria,17035491,6
9,22.1,Blood lactate dehydrogenase increased,17035491,6
10,22.1,Leukopenia,17035491,6
11,22.1,Diarrhoea,17035491,6
12,22.1,Metastases to lung,17035491,6
0,22.1,Malignant neoplasm progression,17035512,5
1,22.1,Product use issue,17035512,6
2,22.1,Breast cancer male,17035512,5
0,22.1,Pneumonia aspiration,17035546,2
0,22.1,Hospitalisation,17035579,6
1,22.1,Prescribed overdose,17035579,6
0,22.1,Dermatitis bullous,17035623,2
0,22.1,Febrile neutropenia,17035650,1
0,22.1,Metastases to bone,17035651,6
1,22.1,Prostatic specific antigen increased,17035651,6
0,22.1,Abdominal discomfort,17035658,6
0,22.1,"Hallucination, auditory",17035754,1
1,22.1,"Hallucination, visual",17035754,1
0,22.1,Ataxia,17035760,2
1,22.1,Toxicity to various agents,17035760,6
2,22.1,Headache,17035760,2
3,22.1,Confusional state,17035760,2
4,22.1,Photophobia,17035760,2
5,22.1,Memory impairment,17035760,2
6,22.1,Visual impairment,17035760,2
7,22.1,Dyskinesia,17035760,2
8,22.1,Drug interaction,17035760,6
0,22.1,Gastrointestinal haemorrhage,17035836,6
1,22.1,Disease progression,17035836,5
2,22.1,Short-bowel syndrome,17035836,6
3,22.1,Gastrointestinal perforation,17035836,6
0,22.1,Disease progression,17035877,1
1,22.1,Metastatic neoplasm,17035877,1
2,22.1,Metastases to meninges,17035877,1
0,22.1,Thrombocytopenia,17035900,6
0,22.1,Underdose,17035937,6
1,22.1,Localised infection,17035937,6
2,22.1,Fatigue,17035937,6
0,22.1,Febrile neutropenia,17036040,1
0,22.1,Febrile neutropenia,17036041,1
0,22.1,Intestinal obstruction,17036061,6
0,22.1,Atrial fibrillation,17036076,1
1,22.1,Muscle spasms,17036076,1
2,22.1,Chest pain,17036076,1
0,22.1,Febrile neutropenia,17036085,1
0,22.1,Drug hypersensitivity,17036169,
0,22.1,Ascites,17036173,6
1,22.1,Metastases to bone,17036173,2
2,22.1,Lymphadenopathy,17036173,6
3,22.1,Mesenteric neoplasm,17036173,6
4,22.1,Hypertension,17036173,6
5,22.1,Metastases to peritoneum,17036173,6
6,22.1,Invasive ductal breast carcinoma,17036173,6
7,22.1,Renal failure,17036173,6
8,22.1,Metastasis,17036173,6
0,22.1,Malignant neoplasm progression,17036182,6
1,22.1,Drug resistance,17036182,6
0,22.1,Hip fracture,17036200,3
0,22.1,Off label use,17036231,6
1,22.1,Hypoacusis,17036231,6
2,22.1,Intentional product use issue,17036231,6
0,22.1,Respiratory failure,17036268,3
1,22.1,Blood bilirubin increased,17036268,3
2,22.1,Thrombosis,17036268,6
3,22.1,Hepatic function abnormal,17036268,3
4,22.1,Drug resistance,17036268,6
5,22.1,Pneumonitis,17036268,6
6,22.1,Drug ineffective,17036268,6
7,22.1,Hepatic cirrhosis,17036268,6
8,22.1,Renal impairment,17036268,2
9,22.1,Coma,17036268,6
10,22.1,Hepatic failure,17036268,5
11,22.1,Metastases to liver,17036268,3
12,22.1,Disease progression,17036268,3
13,22.1,Hepatitis,17036268,3
14,22.1,Hepatic encephalopathy,17036268,6
0,22.1,Thyroid cancer metastatic,17036302,6
1,22.1,Spinal cord compression,17036302,6
2,22.1,Quadriplegia,17036302,6
3,22.1,Disease progression,17036302,6
0,22.1,Immunodeficiency,17036305,5
1,22.1,Infection,17036305,5
0,22.1,Breast cancer metastatic,17036344,6
1,22.1,Malignant neoplasm progression,17036344,6
0,22.1,Renal haemorrhage,17036366,3
0,22.1,Atrial fibrillation,17036373,6
1,22.1,Bundle branch block left,17036373,6
0,22.1,Respiratory failure,17036391,5
1,22.1,Aspiration,17036391,6
2,22.1,Gastric ulcer,17036391,6
3,22.1,Duodenal ulcer,17036391,6
0,22.1,Neurotoxicity,17036531,6
0,22.1,Gastrointestinal tract mucosal pigmentation,17036638,2
1,22.1,Megacolon,17036638,2
2,22.1,Loss of consciousness,17036638,5
3,22.1,General physical health deterioration,17036638,5
4,22.1,Pulmonary artery thrombosis,17036638,5
5,22.1,Dehydration,17036638,2
6,22.1,Impaired gastric emptying,17036638,2
7,22.1,Pulmonary embolism,17036638,5
8,22.1,Abdominal distension,17036638,2
9,22.1,Intra-abdominal pressure increased,17036638,6
10,22.1,Hypercoagulation,17036638,6
11,22.1,Neutrophil count decreased,17036638,6
12,22.1,Visceral congestion,17036638,5
13,22.1,Nausea,17036638,2
14,22.1,Intestinal ischaemia,17036638,6
15,22.1,Vasospasm,17036638,5
16,22.1,Ileus,17036638,2
17,22.1,Blood pressure decreased,17036638,5
18,22.1,Faecaloma,17036638,2
0,22.1,Haematuria,17036668,6
1,22.1,Sepsis,17036668,6
2,22.1,Gait inability,17036668,6
0,22.1,Ocular discomfort,17036696,6
1,22.1,Metastases to central nervous system,17036696,6
2,22.1,Drug resistance,17036696,6
3,22.1,Visual impairment,17036696,6
4,22.1,Malignant neoplasm progression,17036696,6
0,22.1,Gastrointestinal disorder,17036722,5
1,22.1,Hypotension,17036722,5
2,22.1,Lactic acidosis,17036722,5
3,22.1,Body height decreased,17036722,6
4,22.1,Neoplasm progression,17036722,5
5,22.1,Renal failure,17036722,5
6,22.1,Ill-defined disorder,17036722,6
0,22.1,Death,17036743,5
0,22.1,Death,17036745,5
0,22.1,Oesophagitis,17036765,1
1,22.1,Vomiting,17036765,1
0,22.1,Infusion related reaction,17036855,1
1,22.1,Erythema,17036855,1
2,22.1,Chest discomfort,17036855,1
3,22.1,Dyspnoea,17036855,1
0,22.1,Delirium,17036875,6
1,22.1,Mental impairment,17036875,2
2,22.1,Vomiting,17036875,2
3,22.1,Pneumonia,17036875,6
4,22.1,Cough,17036875,6
5,22.1,Confusional state,17036875,6
6,22.1,Nausea,17036875,2
7,22.1,Neutropenia,17036875,6
8,22.1,Sepsis,17036875,6
0,22.1,Hepatic failure,17036878,5
0,22.1,Dyschezia,17036879,1
1,22.1,Tooth loss,17036879,1
2,22.1,Mastication disorder,17036879,1
3,22.1,Feeling abnormal,17036879,1
4,22.1,Constipation,17036879,1
0,22.1,Incorrect dose administered,17036903,6
1,22.1,Weight decreased,17036903,3
2,22.1,Asthenia,17036903,3
3,22.1,Hypotonia,17036903,6
4,22.1,Off label use,17036903,6
5,22.1,Surgery,17036903,6
0,22.1,Tremor,17036907,6
1,22.1,Renal disorder,17036907,6
0,22.1,Pulmonary alveolar haemorrhage,17036911,6
0,22.1,Asphyxia,17036922,1
1,22.1,Asphyxia,17036922,3
2,22.1,Pyrexia,17036922,1
3,22.1,Product dose omission,17036922,6
4,22.1,Pain in extremity,17036922,3
5,22.1,Acute respiratory distress syndrome,17036922,2
6,22.1,Weight decreased,17036922,1
7,22.1,Pyrexia,17036922,3
8,22.1,Pyrexia,17036922,3
9,22.1,Pneumonia,17036922,1
10,22.1,Incoherent,17036922,3
11,22.1,Temperature regulation disorder,17036922,3
12,22.1,Lung disorder,17036922,3
13,22.1,Seizure,17036922,2
14,22.1,Respiratory distress,17036922,3
15,22.1,Drug ineffective,17036922,2
16,22.1,Malaise,17036922,2
17,22.1,Tachypnoea,17036922,3
18,22.1,Pulmonary pain,17036922,3
19,22.1,Hyperhidrosis,17036922,3
20,22.1,Inappropriate schedule of product administration,17036922,6
21,22.1,Malignant neoplasm progression,17036922,3
22,22.1,Pulmonary pain,17036922,2
23,22.1,Chills,17036922,3
24,22.1,Intracranial mass,17036922,3
25,22.1,Weight decreased,17036922,6
0,22.1,Spinal column injury,17036949,6
0,22.1,Urinary retention,17036958,2
1,22.1,Dysuria,17036958,2
0,22.1,Rash,17036999,2
0,22.1,Peritoneal tuberculosis,17037045,6
1,22.1,Osteoporotic fracture,17037045,6
2,22.1,Pathological fracture,17037045,6
3,22.1,Depression,17037045,6
0,22.1,Musculoskeletal disorder,17037056,3
1,22.1,Intellectual disability,17037056,3
2,22.1,Asthenia,17037056,3
3,22.1,Rash,17037056,1
4,22.1,Fatigue,17037056,3
5,22.1,Memory impairment,17037056,3
0,22.1,Neoplasm progression,17037068,6
0,22.1,Pemphigoid,17037076,3
0,22.1,Oral mucosal blistering,17037090,6
1,22.1,Fatigue,17037090,6
2,22.1,Lip blister,17037090,6
3,22.1,Rash macular,17037090,6
0,22.1,Pneumatosis intestinalis,17037097,1
0,22.1,Death,17037157,5
0,22.1,Pulmonary alveolar haemorrhage,17037175,5
1,22.1,White blood cell count increased,17037175,2
2,22.1,Platelet count decreased,17037175,6
0,22.1,Mucosal inflammation,17037196,6
1,22.1,Pneumonitis,17037196,6
2,22.1,Vaginal ulceration,17037196,6
3,22.1,Off label use,17037196,6
0,22.1,Haemoptysis,17037208,5
1,22.1,Bronchial fistula,17037208,5
0,22.1,Anaemia,17037228,3
0,22.1,Alopecia,17037230,6
0,22.1,Alopecia,17037231,3
1,22.1,Hair colour changes,17037231,3
2,22.1,Madarosis,17037231,3
3,22.1,Hair texture abnormal,17037231,3
4,22.1,Hair disorder,17037231,3
0,22.1,Hypoacusis,17037244,6
0,22.1,Peripheral swelling,17037245,6
0,22.1,Intentional product misuse,17037280,6
1,22.1,Abdominal pain upper,17037280,6
2,22.1,Muscular weakness,17037280,6
3,22.1,Vaginal haemorrhage,17037280,6
0,22.1,Cough,17037291,6
1,22.1,Pneumonia,17037291,2
2,22.1,Wheezing,17037291,6
3,22.1,Fatigue,17037291,6
4,22.1,Diarrhoea,17037291,6
0,22.1,Cancer pain,17037298,6
0,22.1,Muscle spasms,17037304,6
1,22.1,Headache,17037304,6
2,22.1,Nasopharyngitis,17037304,6
0,22.1,Product dose omission,17037308,6
1,22.1,Nausea,17037308,1
0,22.1,White blood cell count decreased,17037309,6
0,22.1,Nausea,17037312,6
0,22.1,White blood cell count decreased,17037317,6
0,22.1,White blood cell disorder,17037318,2
0,22.1,Asthenia,17037320,6
1,22.1,Mood altered,17037320,6
0,22.1,Weight increased,17037330,6
1,22.1,Back disorder,17037330,6
2,22.1,Dyspnoea,17037330,6
0,22.1,Neutrophil count decreased,17037342,3
1,22.1,Second primary malignancy,17037342,3
2,22.1,Uterine cancer,17037342,3
0,22.1,Vomiting,17037365,1
1,22.1,Nausea,17037365,1
2,22.1,Post procedural haematoma,17037365,1
0,22.1,Death,17037393,5
0,22.1,Diarrhoea,17037401,6
0,22.1,Alopecia,17037413,3
1,22.1,Hair texture abnormal,17037413,3
2,22.1,Hair disorder,17037413,3
3,22.1,Hair colour changes,17037413,3
0,22.1,Pain,17037471,2
1,22.1,Infarction,17037471,3
2,22.1,Arterial occlusive disease,17037471,3
0,22.1,Palmar-plantar erythrodysaesthesia syndrome,17037529,1
1,22.1,Pneumonia aspiration,17037529,1
0,22.1,Chills,17037541,6
1,22.1,Asphyxia,17037541,6
2,22.1,Anaphylactic reaction,17037541,6
0,22.1,Dyspnoea,17037556,5
1,22.1,Acute respiratory failure,17037556,5
0,22.1,Hepatitis toxic,17037557,1
0,22.1,Malignant neoplasm progression,17037566,6
1,22.1,Ascites,17037566,6
2,22.1,Breast cancer metastatic,17037566,6
3,22.1,Metastases to peritoneum,17037566,6
4,22.1,Renal failure,17037566,6
5,22.1,Hypertension,17037566,6
6,22.1,Gait disturbance,17037566,2
0,22.1,Anaemia,17037672,1
1,22.1,Anaemia,17037672,1
2,22.1,Rectal haemorrhage,17037672,1
3,22.1,Gastrointestinal haemorrhage,17037672,1
0,22.1,Leukopenia,17037675,3
1,22.1,Thrombocytopenia,17037675,1
2,22.1,Haematochezia,17037675,1
3,22.1,Blood pressure systolic increased,17037675,2
0,22.1,Circulatory collapse,17037771,1
1,22.1,Erythema,17037771,1
0,22.1,Fulminant type 1 diabetes mellitus,17037778,2
0,22.1,Bone marrow failure,17037787,6
1,22.1,Malignant neoplasm progression,17037787,5
0,22.1,Fatigue,17037826,6
1,22.1,White blood cell count decreased,17037826,1
2,22.1,Pyrexia,17037826,6
3,22.1,Bone marrow failure,17037826,1
0,22.1,Pancytopenia,17037868,5
0,22.1,Malignant neoplasm progression,17037926,5
0,22.1,Condition aggravated,17037934,6
1,22.1,Interstitial lung disease,17037934,5
0,22.1,Death,17037937,5
1,22.1,Neutrophil count decreased,17037937,1
2,22.1,Taste disorder,17037937,3
3,22.1,Diarrhoea,17037937,3
0,22.1,Death,17037938,5
0,22.1,Encephalitis viral,17037939,2
1,22.1,Opsoclonus myoclonus,17037939,1
2,22.1,Hypogammaglobulinaemia,17037939,6
3,22.1,Rash,17037939,6
0,22.1,Pharyngeal swelling,17037940,3
1,22.1,Dysphagia,17037940,3
0,22.1,Ageusia,17037948,6
1,22.1,Weight decreased,17037948,6
2,22.1,Decreased appetite,17037948,6
3,22.1,Diarrhoea,17037948,6
4,22.1,Renal impairment,17037948,6
5,22.1,Dry mouth,17037948,6
6,22.1,Blood pressure increased,17037948,6
0,22.1,Liver disorder,17037961,6
1,22.1,Vanishing bile duct syndrome,17037961,6
0,22.1,Infection,17037980,5
0,22.1,Metastases to central nervous system,17037993,5
1,22.1,Malignant neoplasm progression,17037993,5
0,22.1,Dyspnoea,17038018,6
1,22.1,Therapy non-responder,17038018,6
2,22.1,Pleural effusion,17038018,6
3,22.1,Metastases to liver,17038018,6
4,22.1,Polyneuropathy,17038018,6
0,22.1,Malignant neoplasm progression,17038078,5
0,22.1,Embolism venous,17038079,2
1,22.1,Rash,17038079,1
2,22.1,Radiation oesophagitis,17038079,6
3,22.1,Infusion related reaction,17038079,1
4,22.1,Appendicitis,17038079,2
5,22.1,Pyrexia,17038079,6
6,22.1,Pulmonary embolism,17038079,2
7,22.1,Radiation pneumonitis,17038079,2
0,22.1,Febrile neutropenia,17038081,1
1,22.1,Toxic epidermal necrolysis,17038081,1
0,22.1,Nausea,17038123,6
1,22.1,Neutropenia,17038123,6
2,22.1,Alopecia,17038123,6
3,22.1,Rhinitis,17038123,6
4,22.1,Toxicity to various agents,17038123,6
5,22.1,Epistaxis,17038123,6
6,22.1,Neurotoxicity,17038123,6
7,22.1,Asthenia,17038123,6
0,22.1,Hot flush,17038151,6
0,22.1,Pulmonary haemorrhage,17038183,2
0,22.1,Death,17038185,5
0,22.1,Pulmonary embolism,17038198,2
1,22.1,Embolism,17038198,2
0,22.1,Hot flush,17038231,3
1,22.1,Blood testosterone decreased,17038231,6
2,22.1,Nausea,17038231,3
3,22.1,Weight decreased,17038231,3
4,22.1,Adverse drug reaction,17038231,6
5,22.1,Malaise,17038231,6
6,22.1,Fatigue,17038231,3
7,22.1,Oedema peripheral,17038231,3
8,22.1,Hyperhidrosis,17038231,3
9,22.1,Decreased appetite,17038231,3
0,22.1,Prostatic specific antigen increased,17038232,6
0,22.1,Adrenal disorder,17038306,3
1,22.1,Interstitial lung disease,17038306,1
0,22.1,Malignant neoplasm progression,17038310,5
0,22.1,Thrombocytopenia,17038412,1
0,22.1,Disease progression,17038413,6
0,22.1,Rash papular,17038416,6
1,22.1,Rash pruritic,17038416,6
2,22.1,Underdose,17038416,6
0,22.1,Disease progression,17038421,6
0,22.1,Thrombocytopenia,17038422,3
0,22.1,Dysgeusia,17038423,2
0,22.1,Anaemia,17038424,1
1,22.1,Thrombocytopenia,17038424,1
2,22.1,Neutrophil count decreased,17038424,2
3,22.1,Hypertension,17038424,2
0,22.1,Cystitis,17038430,1
1,22.1,Atrial fibrillation,17038430,1
0,22.1,Dyspnoea,17038432,6
1,22.1,Weight decreased,17038432,6
2,22.1,Cough,17038432,6
3,22.1,Pneumocystis jirovecii pneumonia,17038432,6
4,22.1,Lethargy,17038432,6
5,22.1,Lung consolidation,17038432,6
6,22.1,Malaise,17038432,6
7,22.1,Pleural effusion,17038432,6
8,22.1,Decreased appetite,17038432,6
0,22.1,Hepatic function abnormal,17038434,1
0,22.1,Death,17038440,5
0,22.1,Neoplasm progression,17038441,3
1,22.1,Diarrhoea,17038441,1
2,22.1,Palmar-plantar erythrodysaesthesia syndrome,17038441,1
3,22.1,Colon cancer recurrent,17038441,3
0,22.1,Malignant neoplasm progression,17038445,6
0,22.1,Death,17038452,5
0,22.1,Dehydration,17038471,3
1,22.1,Constipation,17038471,3
2,22.1,Product dose omission,17038471,6
3,22.1,Asthenia,17038471,3
4,22.1,Ageusia,17038471,3
5,22.1,Confusional state,17038471,3
6,22.1,Nausea,17038471,3
7,22.1,Death,17038471,5
8,22.1,Abdominal pain,17038471,3
9,22.1,Taste disorder,17038471,3
10,22.1,Fall,17038471,3
0,22.1,Abdominal pain lower,17038523,3
1,22.1,Urinary tract infection,17038523,6
2,22.1,Nephrolithiasis,17038523,6
3,22.1,Kidney infection,17038523,3
4,22.1,Urethral obstruction,17038523,3
5,22.1,Renal neoplasm,17038523,6
0,22.1,Loss of consciousness,17038538,1
0,22.1,Immune-mediated dermatitis,17038551,6
0,22.1,Treatment failure,17038562,1
0,22.1,Non-small cell lung cancer metastatic,17038565,6
0,22.1,Seizure,17038567,6
1,22.1,Pneumonia bacterial,17038567,6
2,22.1,Lung disorder,17038567,2
3,22.1,Cardiac failure congestive,17038567,5
4,22.1,Taste disorder,17038567,3
5,22.1,Cardio-respiratory arrest,17038567,6
0,22.1,Malignant neoplasm progression,17038596,5
0,22.1,Neutropenia,17038603,1
0,22.1,Alopecia,17038608,3
1,22.1,Fatigue,17038608,3
2,22.1,White blood cell count decreased,17038608,3
0,22.1,Neoplasm progression,17038611,6
0,22.1,Wheezing,17038613,6
1,22.1,Cough,17038613,6
0,22.1,Death,17038636,5
0,22.1,Chills,17038735,6
1,22.1,Back pain,17038735,6
2,22.1,Purpura,17038735,6
3,22.1,Thrombocytopenia,17038735,1
4,22.1,Pyrexia,17038735,6
5,22.1,Product use in unapproved indication,17038735,6
0,22.1,Malignant neoplasm progression,17038788,6
1,22.1,Breast cancer metastatic,17038788,6
2,22.1,Diverticulum intestinal,17038788,6
3,22.1,Cholelithiasis,17038788,6
0,22.1,Treatment failure,17038808,1
0,22.1,Malignant neoplasm progression,17038844,6
1,22.1,Renal colic,17038844,6
2,22.1,Anaemia,17038844,6
3,22.1,Spinal pain,17038844,6
4,22.1,Paraesthesia,17038844,6
5,22.1,Product intolerance,17038844,6
6,22.1,Anxiety disorder,17038844,6
7,22.1,Pollakiuria,17038844,6
8,22.1,Thrombocytopenia,17038844,6
9,22.1,Inappropriate schedule of product administration,17038844,6
10,22.1,Dysuria,17038844,6
0,22.1,Duodenal perforation,17038878,6
0,22.1,Cardiac discomfort,17038879,6
1,22.1,Dyspnoea,17038879,6
0,22.1,Hepatic hydrothorax,17038880,2
0,22.1,Gastrointestinal disorder,17038882,6
1,22.1,Respiratory disorder,17038882,1
2,22.1,Vomiting,17038882,6
0,22.1,Lung disorder,17038888,1
0,22.1,Dyspnoea,17038890,2
1,22.1,Anaemia,17038890,1
0,22.1,Febrile neutropenia,17038905,6
1,22.1,Aortitis,17038905,1
0,22.1,Acute kidney injury,17038908,3
0,22.1,Treatment failure,17038918,3
0,22.1,Tubulointerstitial nephritis,17038926,6
1,22.1,Melaena,17038926,6
2,22.1,Fall,17038926,6
3,22.1,Ligament sprain,17038926,6
4,22.1,Bone pain,17038926,6
5,22.1,Pneumonia,17038926,1
6,22.1,Eczema,17038926,6
7,22.1,Acute kidney injury,17038926,2
8,22.1,Hypoaesthesia,17038926,6
0,22.1,Death,17038930,5
0,22.1,Tooth infection,17038932,1
0,22.1,Diarrhoea,17039020,1
1,22.1,Clostridial infection,17039020,1
0,22.1,General physical health deterioration,17039023,1
0,22.1,Back disorder,17039032,6
1,22.1,Weight decreased,17039032,6
2,22.1,Diverticulitis,17039032,6
0,22.1,Haemorrhage,17039050,5
0,22.1,Psychological trauma,17039060,6
1,22.1,Impaired quality of life,17039060,6
2,22.1,Anxiety,17039060,6
3,22.1,Emotional distress,17039060,6
4,22.1,Pain,17039060,6
5,22.1,Alopecia,17039060,2
0,22.1,Alopecia,17039101,2
1,22.1,Emotional distress,17039101,6
2,22.1,Anxiety,17039101,6
3,22.1,Pain,17039101,6
4,22.1,Impaired quality of life,17039101,6
0,22.1,Emotional distress,17039110,6
1,22.1,Anxiety,17039110,6
2,22.1,Psychological trauma,17039110,6
3,22.1,Pain,17039110,6
4,22.1,Alopecia,17039110,3
5,22.1,Impaired quality of life,17039110,6
0,22.1,Alopecia,17039155,2
1,22.1,Psychological trauma,17039155,6
0,22.1,Alopecia,17039158,2
1,22.1,Impaired quality of life,17039158,6
2,22.1,Psychological trauma,17039158,6
3,22.1,Emotional distress,17039158,6
4,22.1,Pain,17039158,6
5,22.1,Anxiety,17039158,6
0,22.1,Alopecia,17039166,2
0,22.1,Alopecia,17039177,2
1,22.1,Psychological trauma,17039177,6
2,22.1,Pain,17039177,6
3,22.1,Anxiety,17039177,6
4,22.1,Emotional distress,17039177,6
5,22.1,Impaired quality of life,17039177,6
0,22.1,Alopecia,17039194,3
0,22.1,Jaundice,17039267,4
1,22.1,Malignant neoplasm progression,17039267,4
0,22.1,Dyspnoea,17039333,3
1,22.1,Deep vein thrombosis,17039333,6
2,22.1,Pneumonitis,17039333,6
3,22.1,Cerebrovascular accident,17039333,6
0,22.1,Autoimmune pancreatitis,17039339,1
0,22.1,Anxiety,17039358,6
1,22.1,Pain,17039358,6
2,22.1,Impaired quality of life,17039358,6
3,22.1,Emotional distress,17039358,6
4,22.1,Alopecia,17039358,3
5,22.1,Psychological trauma,17039358,6
0,22.1,Anaemia,17039362,1
1,22.1,Blood count abnormal,17039362,6
2,22.1,Vomiting,17039362,1
3,22.1,Transfusion,17039362,6
4,22.1,Restless legs syndrome,17039362,3
5,22.1,Nausea,17039362,1
6,22.1,Haematuria,17039362,1
7,22.1,Hypotension,17039362,6
8,22.1,Asthenia,17039362,3
9,22.1,Blood urine present,17039362,6
10,22.1,Drug intolerance,17039362,6
11,22.1,Ageusia,17039362,1
12,22.1,Decreased appetite,17039362,1
0,22.1,Alopecia,17039375,3
0,22.1,Psychological trauma,17039380,6
1,22.1,Alopecia,17039380,2
0,22.1,Alopecia,17039393,2
1,22.1,Psychological trauma,17039393,6
0,22.1,Psychological trauma,17039400,6
1,22.1,Alopecia,17039400,2
0,22.1,Psychological trauma,17039412,6
1,22.1,Alopecia,17039412,2
0,22.1,Emotional distress,17039423,6
1,22.1,Anxiety,17039423,6
2,22.1,Pain,17039423,6
3,22.1,Impaired quality of life,17039423,6
4,22.1,Alopecia,17039423,2
0,22.1,Pain,17039425,6
1,22.1,Emotional distress,17039425,6
2,22.1,Anxiety,17039425,6
3,22.1,Impaired quality of life,17039425,6
4,22.1,Alopecia,17039425,2
5,22.1,Psychological trauma,17039425,6
0,22.1,Transitional cell carcinoma,17039434,3
0,22.1,Blood alkaline phosphatase increased,17039441,1
1,22.1,Dermatitis exfoliative generalised,17039441,2
2,22.1,Steatorrhoea,17039441,6
3,22.1,Pancreatitis chronic,17039441,1
4,22.1,Aspartate aminotransferase increased,17039441,1
5,22.1,Alanine aminotransferase increased,17039441,1
0,22.1,Neuropathy peripheral,17039445,2
1,22.1,Lethargy,17039445,6
2,22.1,Pain in extremity,17039445,2
3,22.1,Fatigue,17039445,6
0,22.1,Product use in unapproved indication,17039446,6
1,22.1,Renal impairment,17039446,1
2,22.1,Adrenocorticotropic hormone deficiency,17039446,1
0,22.1,Death,17039449,5
0,22.1,Product administration error,17039453,
1,22.1,Underdose,17039453,
2,22.1,Needle issue,17039453,
3,22.1,Wrong technique in product usage process,17039453,
0,22.1,Death,17039454,5
0,22.1,Device leakage,17039458,
1,22.1,Wrong technique in product usage process,17039458,
2,22.1,Syringe issue,17039458,
3,22.1,Product physical consistency issue,17039458,
4,22.1,Intercepted product preparation error,17039458,
0,22.1,Death,17039466,5
0,22.1,Inappropriate schedule of product administration,17039469,6
1,22.1,Pyrexia,17039469,6
2,22.1,Fatigue,17039469,6
3,22.1,Depression,17039469,6
4,22.1,General physical health deterioration,17039469,6
5,22.1,Productive cough,17039469,6
6,22.1,Tooth abscess,17039469,6
7,22.1,Rhinitis allergic,17039469,6
8,22.1,Mood disorder due to a general medical condition,17039469,6
9,22.1,Blood corticotrophin increased,17039469,6
0,22.1,Diarrhoea,17039506,3
1,22.1,Neck mass,17039506,6
2,22.1,Pruritus,17039506,3
3,22.1,Dry mouth,17039506,6
4,22.1,Decreased appetite,17039506,3
5,22.1,Haemorrhage,17039506,3
6,22.1,Gingival bleeding,17039506,3
7,22.1,Weight decreased,17039506,3
8,22.1,Oral pain,17039506,3
9,22.1,Cough,17039506,1
10,22.1,Immunodeficiency,17039506,3
11,22.1,Erythema,17039506,6
12,22.1,Cheilitis,17039506,6
13,22.1,Herpes virus infection,17039506,3
14,22.1,Nail disorder,17039506,3
15,22.1,Pain,17039506,6
16,22.1,Nail disorder,17039506,3
17,22.1,Abdominal pain,17039506,1
18,22.1,Oral mucosal erythema,17039506,3
0,22.1,Embolism,17039558,3
0,22.1,General physical health deterioration,17039559,3
1,22.1,Anal abscess,17039559,3
0,22.1,Death,17039573,5
0,22.1,Insomnia,17039591,6
1,22.1,Mania,17039591,6
0,22.1,Swelling of eyelid,17039597,2
1,22.1,Abdominal pain,17039597,2
2,22.1,Pruritus,17039597,1
3,22.1,Diarrhoea,17039597,1
4,22.1,Erythema,17039597,2
5,22.1,Rash,17039597,1
6,22.1,Skin swelling,17039597,2
0,22.1,Skin ulcer,17039607,2
0,22.1,Pharyngeal ulceration,17039608,3
0,22.1,Acquired tracheo-oesophageal fistula,17039611,5
1,22.1,Palmar-plantar erythrodysaesthesia syndrome,17039611,2
2,22.1,Dysphonia,17039611,2
3,22.1,Malignant neoplasm progression,17039611,2
0,22.1,Disease progression,17039627,6
0,22.1,Skin ulcer,17039644,1
1,22.1,Swelling,17039644,6
2,22.1,Induration,17039644,6
0,22.1,Diarrhoea,17039668,6
0,22.1,Cerebral haemorrhage,17039669,6
0,22.1,Pneumonitis,17039670,5
1,22.1,Interstitial lung disease,17039670,5
2,22.1,Respiratory failure,17039670,5
3,22.1,Condition aggravated,17039670,5
0,22.1,Malignant neoplasm progression,17039675,6
1,22.1,Breast cancer,17039675,6
2,22.1,Metastases to liver,17039675,6
0,22.1,Vomiting,17039698,2
1,22.1,Nausea,17039698,2
2,22.1,Bone marrow failure,17039698,2
0,22.1,Off label use,17039705,6
1,22.1,Small cell lung cancer metastatic,17039705,5
0,22.1,Death,17039771,5
0,22.1,Secondary adrenocortical insufficiency,17039793,3
0,22.1,Arthritis,17039821,6
0,22.1,Constipation,17039822,3
1,22.1,Abdominal pain upper,17039822,1
2,22.1,Back pain,17039822,1
3,22.1,Back pain,17039822,3
4,22.1,Abdominal pain upper,17039822,3
5,22.1,Constipation,17039822,1
0,22.1,Rhabdomyolysis,17039825,1
1,22.1,Drug interaction,17039825,1
2,22.1,Wheelchair user,17039825,1
3,22.1,Gait disturbance,17039825,1
4,22.1,Toxicity to various agents,17039825,1
0,22.1,Abdominal pain,17039840,1
1,22.1,Flank pain,17039840,1
2,22.1,Vomiting,17039840,1
3,22.1,Urinary tract infection,17039840,1
4,22.1,Pain,17039840,1
5,22.1,Nausea,17039840,1
0,22.1,Diarrhoea,17039842,3
1,22.1,Product residue present,17039842,3
2,22.1,Nausea,17039842,3
3,22.1,Constipation,17039842,3
0,22.1,Asthenia,17039870,6
1,22.1,Nausea,17039870,6
2,22.1,Neutropenia,17039870,6
3,22.1,Anxiety,17039870,6
0,22.1,Thrombocytopenia,17039894,1
1,22.1,Anaphylactic reaction,17039894,1
2,22.1,Drug-induced liver injury,17039894,1
0,22.1,Chills,17039904,6
1,22.1,Pyrexia,17039904,6
2,22.1,Neutropenic sepsis,17039904,3
0,22.1,Neurodegenerative disorder,17039935,6
0,22.1,Prinzmetal angina,17039939,6
0,22.1,Dizziness,17040083,6
1,22.1,Intracranial pressure increased,17040083,6
2,22.1,Toxicity to various agents,17040083,6
3,22.1,Vertigo,17040083,6
4,22.1,Feeling abnormal,17040083,6
5,22.1,Headache,17040083,6
6,22.1,Haemoglobin abnormal,17040083,6
7,22.1,Vomiting,17040083,6
8,22.1,Hypokinesia,17040083,2
9,22.1,Osteitis,17040083,6
10,22.1,Muscular weakness,17040083,6
11,22.1,Asthenia,17040083,6
0,22.1,Off label use,17040202,6
1,22.1,Death,17040202,5
0,22.1,Ammonia increased,17040259,1
1,22.1,Coma,17040259,1
2,22.1,Hepatic encephalopathy,17040259,1
0,22.1,Renal impairment,17040516,6
1,22.1,Intestinal obstruction,17040516,6
2,22.1,Asthenia,17040516,6
3,22.1,Hernia,17040516,6
0,22.1,Osteonecrosis of jaw,17040518,3
0,22.1,Tremor,17040523,1
1,22.1,Chills,17040523,1
2,22.1,Hypertension,17040523,1
3,22.1,Body temperature increased,17040523,1
0,22.1,Mucosal inflammation,17040525,1
0,22.1,Death,17040527,5
0,22.1,Electrocardiogram ST segment depression,17040529,6
1,22.1,Electrocardiogram T wave inversion,17040529,6
2,22.1,Supraventricular extrasystoles,17040529,6
3,22.1,Ventricular extrasystoles,17040529,6
4,22.1,Ejection fraction decreased,17040529,6
0,22.1,Death,17040530,5
0,22.1,Hypertension,17040575,6
1,22.1,Therapy partial responder,17040575,6
2,22.1,Atypical haemolytic uraemic syndrome,17040575,6
3,22.1,Acute kidney injury,17040575,6
4,22.1,Anaemia,17040575,6
5,22.1,Thrombosis,17040575,6
6,22.1,Blood lactate dehydrogenase increased,17040575,6
7,22.1,Asthenia,17040575,6
8,22.1,Decreased appetite,17040575,6
9,22.1,Oedema peripheral,17040575,6
10,22.1,Normochromic anaemia,17040575,6
11,22.1,Thrombocytopenia,17040575,6
0,22.1,Toxicity to various agents,17040808,6
1,22.1,Foetal exposure during pregnancy,17040808,6
2,22.1,Dilatation ventricular,17040808,6
0,22.1,Electrocardiogram QT prolonged,17040820,1
0,22.1,Nail disorder,17040845,6
1,22.1,Granuloma,17040845,6
0,22.1,Posterior reversible encephalopathy syndrome,17040850,1
0,22.1,Toxicity to various agents,17040857,6
1,22.1,Neurotoxicity,17040857,6
2,22.1,Asthenia,17040857,6
3,22.1,Rhinitis,17040857,6
4,22.1,Alopecia,17040857,6
5,22.1,Neutropenia,17040857,6
6,22.1,Diarrhoea,17040857,6
7,22.1,Nausea,17040857,6
8,22.1,Epistaxis,17040857,6
0,22.1,Bone marrow failure,17040860,2
0,22.1,Disease progression,17040878,6
1,22.1,Hypersensitivity,17040878,6
0,22.1,Hypersensitivity,17040883,6
1,22.1,Disease progression,17040883,6
0,22.1,Dysarthria,17040929,1
1,22.1,Eyelid ptosis,17040929,1
2,22.1,Asthenia,17040929,1
3,22.1,Tremor,17040929,1
4,22.1,Bronchospasm,17040929,1
0,22.1,Death,17040933,5
0,22.1,Palmar-plantar erythrodysaesthesia syndrome,17040936,6
1,22.1,Leukopenia,17040936,6
2,22.1,Infection,17040936,6
3,22.1,Hepatic function abnormal,17040936,6
4,22.1,Neutropenia,17040936,6
5,22.1,Thrombocytopenia,17040936,6
6,22.1,Anaemia,17040936,6
7,22.1,Decreased appetite,17040936,6
8,22.1,Renal impairment,17040936,6
0,22.1,Thrombosis,17040946,2
1,22.1,Pulmonary embolism,17040946,2
2,22.1,Pulmonary hypertension,17040946,2
0,22.1,Off label use,17041044,6
0,22.1,Death,17041172,5
0,22.1,Hypercalcaemia,17041266,2
0,22.1,Fatigue,17041276,6
1,22.1,Intestinal obstruction,17041276,6
2,22.1,Diarrhoea,17041276,6
0,22.1,Completed suicide,17041296,5
0,22.1,Death,17041375,5
0,22.1,Pyrexia,17041380,6
1,22.1,Malaise,17041380,6
2,22.1,Tremor,17041380,6
3,22.1,Chills,17041380,6
0,22.1,Diarrhoea,17041388,6
1,22.1,Peripheral sensory neuropathy,17041388,6
2,22.1,Febrile neutropenia,17041388,6
3,22.1,Neutropenia,17041388,6
4,22.1,Fatigue,17041388,6
5,22.1,Transaminases abnormal,17041388,6
6,22.1,Pneumothorax,17041388,6
0,22.1,Death,17041393,5
0,22.1,Flatulence,17041450,6
1,22.1,Diarrhoea,17041450,6
2,22.1,Dyspepsia,17041450,6
3,22.1,Asthenia,17041450,6
4,22.1,Gait disturbance,17041450,6
5,22.1,Arthralgia,17041450,6
0,22.1,Oedema peripheral,17041481,1
1,22.1,Non-cirrhotic portal hypertension,17041481,1
2,22.1,Venoocclusive liver disease,17041481,1
3,22.1,Cholestasis,17041481,1
4,22.1,Ascites,17041481,1
5,22.1,Alanine aminotransferase increased,17041481,1
6,22.1,Thrombocytopenia,17041481,6
7,22.1,Aspartate aminotransferase increased,17041481,6
8,22.1,Blood bilirubin increased,17041481,6
0,22.1,Sepsis,17041488,5
0,22.1,Clostridium difficile infection,17041491,6
1,22.1,Neutropenic sepsis,17041491,1
0,22.1,Delirium,17041500,1
1,22.1,Delusion,17041500,6
2,22.1,Cognitive disorder,17041500,6
0,22.1,Diplopia,17041501,1
0,22.1,White blood cell count decreased,17041506,6
0,22.1,Death,17041512,5
1,22.1,Intentional product use issue,17041512,6
0,22.1,Venoocclusive disease,17041513,1
0,22.1,Neuropathy peripheral,17041549,6
1,22.1,Hypoaesthesia,17041549,6
0,22.1,Rash,17041557,3
1,22.1,Prostate cancer,17041557,5
0,22.1,Febrile neutropenia,17041568,1
1,22.1,Anaemia,17041568,1
2,22.1,Thrombocytopenia,17041568,1
0,22.1,Bone marrow failure,17041573,2
0,22.1,Campylobacter colitis,17041586,1
0,22.1,Metastases to pelvis,17041623,6
0,22.1,Thyroiditis,17041628,3
0,22.1,Neutropenic sepsis,17041640,6
1,22.1,Glycosylated haemoglobin increased,17041640,6
2,22.1,Diabetic ketoacidosis,17041640,6
3,22.1,Atrial fibrillation,17041640,6
4,22.1,Type 2 diabetes mellitus,17041640,3
0,22.1,Malignant neoplasm progression,17041673,6
1,22.1,Breast cancer,17041673,6
0,22.1,Thrombocytopenia,17041677,6
1,22.1,Non-cirrhotic portal hypertension,17041677,6
2,22.1,Splenomegaly,17041677,6
3,22.1,Nodular regenerative hyperplasia,17041677,6
4,22.1,Portal hypertensive gastropathy,17041677,6
5,22.1,Cholestasis,17041677,6
0,22.1,Dyskinesia,17041685,2
1,22.1,Ataxia,17041685,2
2,22.1,Confusional state,17041685,2
3,22.1,Memory impairment,17041685,2
4,22.1,Drug interaction,17041685,2
5,22.1,Visual impairment,17041685,2
6,22.1,Headache,17041685,2
7,22.1,Photophobia,17041685,2
8,22.1,Toxicity to various agents,17041685,2
0,22.1,Urinary tract infection,17041723,1
1,22.1,Sepsis,17041723,1
0,22.1,Dyspnoea,17041743,2
1,22.1,Embolism,17041743,2
2,22.1,Muscular weakness,17041743,2
0,22.1,Neuropathy peripheral,17041871,1
1,22.1,Dysgeusia,17041871,1
0,22.1,Asthenia,17041908,5
1,22.1,Vomiting,17041908,5
2,22.1,Metastases to spine,17041908,5
3,22.1,Metastases to soft tissue,17041908,5
4,22.1,Nausea,17041908,5
5,22.1,Drug intolerance,17041908,5
0,22.1,Gastrointestinal toxicity,17041911,6
1,22.1,Neurotoxicity,17041911,6
2,22.1,Haematotoxicity,17041911,6
0,22.1,Infection,17041941,5
1,22.1,Cholestasis,17041941,5
0,22.1,Hyperammonaemia,17042037,6
1,22.1,Altered state of consciousness,17042037,6
0,22.1,Altered state of consciousness,17042040,6
1,22.1,Hyperammonaemia,17042040,6
0,22.1,Arteriospasm coronary,17042043,1
0,22.1,Altered state of consciousness,17042087,6
1,22.1,Hyperammonaemia,17042087,6
0,22.1,Hyperammonaemia,17042088,6
1,22.1,Altered state of consciousness,17042088,6
0,22.1,Hyperammonaemia,17042125,6
1,22.1,Altered state of consciousness,17042125,6
0,22.1,Confusional state,17042129,6
1,22.1,Hallucination,17042129,1
2,22.1,Product use in unapproved indication,17042129,6
0,22.1,Bone marrow failure,17042201,6
0,22.1,Drug resistance,17042210,6
0,22.1,Chest pain,17042217,6
0,22.1,Metastases to lung,17042240,3
1,22.1,Product availability issue,17042240,6
2,22.1,Feeling abnormal,17042240,3
0,22.1,Cardiac failure,17042245,6
0,22.1,Febrile neutropenia,17042247,1
0,22.1,Loss of consciousness,17042281,6
1,22.1,Abdominal pain upper,17042281,6
2,22.1,Eye movement disorder,17042281,6
3,22.1,Chest pain,17042281,6
0,22.1,Bone pain,17042308,6
1,22.1,Ill-defined disorder,17042308,6
2,22.1,Malaise,17042308,6
3,22.1,Pain in extremity,17042308,6
4,22.1,Dysuria,17042308,6
5,22.1,Arthralgia,17042308,6
6,22.1,Pancreatitis,17042308,6
7,22.1,Posterior reversible encephalopathy syndrome,17042308,6
8,22.1,Limb mass,17042308,6
9,22.1,Dehydration,17042308,6
0,22.1,Drug eruption,17042328,6
1,22.1,Metastases to liver,17042328,6
0,22.1,Death,17042346,5
0,22.1,Amnesia,17042352,1
1,22.1,Inappropriate schedule of product administration,17042352,6
2,22.1,Off label use,17042352,6
0,22.1,Interstitial lung disease,17042474,5
0,22.1,Interstitial lung disease,17042538,6
0,22.1,Nausea,17042558,6
0,22.1,Full blood count decreased,17042589,6
1,22.1,White blood cell count decreased,17042589,1
2,22.1,Platelet count decreased,17042589,1
3,22.1,Oral mucosal eruption,17042589,1
4,22.1,Red blood cell count decreased,17042589,1
0,22.1,Catheter site thrombosis,17042624,1
0,22.1,Blood creatine phosphokinase increased,17042664,6
1,22.1,Myopathy,17042664,6
0,22.1,Palpitations,17042683,6
1,22.1,Product use issue,17042683,6
2,22.1,Product dose omission,17042683,6
3,22.1,Malaise,17042683,3
4,22.1,Off label use,17042683,6
5,22.1,Hypothyroidism,17042683,6
6,22.1,Supraventricular tachycardia,17042683,6
0,22.1,Bone marrow failure,17042692,6
1,22.1,Diarrhoea,17042692,6
2,22.1,Hypersensitivity,17042692,6
3,22.1,Nausea,17042692,6
4,22.1,Acute kidney injury,17042692,6
5,22.1,Dehydration,17042692,6
6,22.1,Palmar-plantar erythrodysaesthesia syndrome,17042692,6
7,22.1,Fatigue,17042692,6
8,22.1,Mucosal inflammation,17042692,6
9,22.1,Neuropathy peripheral,17042692,6
10,22.1,Decreased appetite,17042692,6
0,22.1,Death,17042732,5
0,22.1,Breast cancer,17042759,5
1,22.1,Acute kidney injury,17042759,3
2,22.1,Hypertension,17042759,1
0,22.1,Blood pressure systolic decreased,17042775,2
1,22.1,Febrile neutropenia,17042775,2
0,22.1,Renal failure,17042782,3
0,22.1,Neutrophil count decreased,17042783,6
1,22.1,Hypertension,17042783,6
0,22.1,Platelet count decreased,17042795,1
1,22.1,White blood cell count increased,17042795,1
2,22.1,Pneumonia aspiration,17042795,1
3,22.1,Pyrexia,17042795,1
4,22.1,Vomiting,17042795,1
0,22.1,Interstitial lung disease,17042798,2
0,22.1,Death,17042810,5
0,22.1,Disease progression,17042839,6
1,22.1,Off label use,17042839,6
0,22.1,Gastrointestinal perforation,17042863,2
1,22.1,Pneumothorax,17042863,6
2,22.1,Fatigue,17042863,6
3,22.1,Neoplasm progression,17042863,6
0,22.1,Death,17042885,5
1,22.1,Off label use,17042885,6
0,22.1,Rash macular,17042904,3
1,22.1,Blood creatinine increased,17042904,3
0,22.1,Prostate cancer metastatic,17042924,6
0,22.1,Product dose omission,17042940,6
1,22.1,Intentional product use issue,17042940,6
0,22.1,Carbohydrate antigen 19-9 increased,17042952,6
1,22.1,Hepatocellular injury,17042952,1
2,22.1,Blood lactate dehydrogenase increased,17042952,1
3,22.1,Vena cava thrombosis,17042952,6
0,22.1,Fatigue,17043031,3
0,22.1,Pneumonia,17043094,5
0,22.1,Dyspepsia,17043121,6
1,22.1,Asthenia,17043121,6
2,22.1,Weight increased,17043121,6
3,22.1,Blood count abnormal,17043121,6
0,22.1,Respiratory disorder,17043128,6
1,22.1,Hypoacusis,17043128,6
0,22.1,Hair disorder,17043139,6
1,22.1,Alopecia,17043139,3
2,22.1,Hair colour changes,17043139,6
3,22.1,Hair texture abnormal,17043139,6
0,22.1,Hair disorder,17043140,6
1,22.1,Alopecia,17043140,3
2,22.1,Hair texture abnormal,17043140,6
3,22.1,Hair colour changes,17043140,6
4,22.1,Madarosis,17043140,3
0,22.1,Product dose omission,17043146,6
1,22.1,Off label use,17043146,6
2,22.1,Memory impairment,17043146,6
3,22.1,Product use in unapproved indication,17043146,6
0,22.1,Malignant neoplasm progression,17043237,6
1,22.1,Laryngeal cancer metastatic,17043237,6
0,22.1,Fatigue,17043248,6
1,22.1,Alopecia,17043248,6
0,22.1,Neoplasm progression,17043277,5
1,22.1,Multiple organ dysfunction syndrome,17043277,5
0,22.1,Urinary ascites,17043333,6
1,22.1,Ureteric stenosis,17043333,6
2,22.1,Malignant neoplasm progression,17043333,6
0,22.1,White blood cell count decreased,17043346,6
1,22.1,Neoplasm progression,17043346,6
0,22.1,Alopecia,17043356,1
1,22.1,Nipple disorder,17043356,1
2,22.1,Stomatitis,17043356,6
0,22.1,Gingival bleeding,17043503,6
1,22.1,Oral mucosal blistering,17043503,6
2,22.1,Diarrhoea,17043503,6
0,22.1,Alopecia,17043506,3
1,22.1,Hair colour changes,17043506,3
2,22.1,Hair texture abnormal,17043506,3
3,22.1,Hair disorder,17043506,3
0,22.1,Acute kidney injury,17043508,1
1,22.1,Creatinine renal clearance decreased,17043508,6
2,22.1,Asthenia,17043508,3
3,22.1,Weight decreased,17043508,1
4,22.1,Blood creatine abnormal,17043508,6
5,22.1,Blood pressure fluctuation,17043508,1
6,22.1,Fatigue,17043508,3
7,22.1,Decreased appetite,17043508,2
8,22.1,Blood urea abnormal,17043508,3
0,22.1,Neoplasm progression,17043521,3
0,22.1,Hair texture abnormal,17043537,3
1,22.1,Alopecia,17043537,3
2,22.1,Hair disorder,17043537,3
3,22.1,Hair colour changes,17043537,3
4,22.1,Madarosis,17043537,3
0,22.1,Neutropenia,17043552,1
1,22.1,Alopecia,17043552,3
2,22.1,Eastern Cooperative Oncology Group performance status worsened,17043552,1
3,22.1,Mitral valve incompetence,17043552,1
4,22.1,Weight decreased,17043552,6
5,22.1,Aphasia,17043552,3
6,22.1,Nausea,17043552,3
7,22.1,Electrocardiogram T wave abnormal,17043552,1
8,22.1,White blood cell count decreased,17043552,6
0,22.1,Urinary tract infection,17043556,6
1,22.1,Joint stiffness,17043556,6
2,22.1,Alopecia,17043556,6
3,22.1,Hot flush,17043556,6
4,22.1,Neoplasm progression,17043556,6
5,22.1,Bone pain,17043556,6
6,22.1,Leukopenia,17043556,6
7,22.1,Fatigue,17043556,6
0,22.1,Myocardial infarction,17043582,5
0,22.1,Death,17043585,
0,22.1,Rash,17043590,
0,22.1,Hospitalisation,17043592,
0,22.1,Laryngitis,17043601,6
0,22.1,Guillain-Barre syndrome,17043647,5
0,22.1,Pneumonia,17043677,5
0,22.1,Death,17043679,
0,22.1,Toxicity to various agents,17043708,
0,22.1,Paraesthesia,17043711,
1,22.1,Hypoaesthesia,17043711,
0,22.1,Death,17043715,
0,22.1,Death,17043725,
0,22.1,Hepatic enzyme increased,17043732,
0,22.1,Bacterial infection,17043746,
1,22.1,Therapy cessation,17043746,
0,22.1,Fatigue,17043768,3
1,22.1,Sensory disturbance,17043768,3
2,22.1,Malaise,17043768,3
3,22.1,Stress,17043768,3
0,22.1,Pyrexia,17043786,6
1,22.1,Death,17043786,5
2,22.1,Platelet count decreased,17043786,6
3,22.1,Infection,17043786,6
0,22.1,Blood pressure decreased,17043792,
1,22.1,Tremor,17043792,
2,22.1,Body temperature increased,17043792,
3,22.1,Infusion related reaction,17043792,
4,22.1,Chest discomfort,17043792,
5,22.1,Throat tightness,17043792,
6,22.1,Defaecation urgency,17043792,
7,22.1,Hyperhidrosis,17043792,
0,22.1,Pulmonary fibrosis,17043830,6
1,22.1,Condition aggravated,17043830,6
0,22.1,Neoplasm progression,17043832,6
1,22.1,Death,17043832,5
